GeneDx Cuts 2026 Revenue Outlook to $475–490M After 34% Volume Surge
GeneDx delivered 34% year-over-year exome and genome test volume growth to 27,488 tests and 17% revenue growth to $102.3 million in Q1 2026, alongside an $8.2 million adjusted net loss. The company reduced full-year revenue guidance to $475–490 million and projects at least 30% volume growth.
1. First Quarter 2026 Financial Results
GeneDx recorded revenue of $102.3 million in Q1 2026, up 17% year-over-year, with exome and genome test revenue rising 27% to $90.6 million. Test volume reached 27,488, a 34% increase, while adjusted gross margin held at 69% and adjusted net loss was $8.2 million.
2. Updated Full-Year 2026 Guidance
Management lowered full-year revenue guidance to $475–490 million from $540–555 million and trimmed expected exome and genome volume growth to at least 30% from 33–35%. Adjusted gross margin is projected at approximately 70%, with an adjusted net loss forecast of $5 million for the year.
3. Strategic Expansion and Clinical Leadership
GeneDx launched the SAVES-Kids study demonstrating up to $80,000 in annual healthcare savings and introduced a reflex genome testing product. It expanded Medicaid coverage by 4.9 million patients, launched a sponsored Niemann-Pick Disease Type C testing program with Zevra Therapeutics, and presented AI-driven genomic research at major medical conferences.